A new nanotechnology treatment reversed Alzheimer’s symptoms in mice by restoring the brain’s natural cleanup system. The specially engineered nanoparticles helped clear toxic amyloid proteins from the brain and repair the blood-brain barrier, which normally protects and regulates the brain’s environment. In one striking experiment, elderly mice treated with the therapy later behaved like healthy younger mice.
Read more HERE
The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults. The drug is the first FDA-approved treatment for this condition that is not an antipsychotic. FDA initially approved Auvelity in 2022 to treat major depressive disorder in adults.
Read more HERE
U.S. Senators Shelley Moore Capito (R-W.Va.) and Amy Klobuchar (D-Minn.) reintroduced bipartisan legislation to bolster training for primary care providers so they can better diagnose Alzheimer’s and other dementia and deliver high-quality, person-centered care in community-based settings.
Read about it HERE
Despite hopes raised by earlier observational studies and biomarker shifts, The Lancet trials found that oral semaglutide did not meaningfully slow clinical progression in early Alzheimer’s disease over two years.
Read it HERE
An earlier diagnosis and intervention strategy for Alzheimer’s disease is on the horizon, signaling a need to overhaul current detection methods and patient care protocols, experts at the Alzheimer’s Association Research Roundtable (AARR) said.
“Advances in biomarker technology, digital cognitive assessments, and amyloid-targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer’s disease,” reported Christopher Weber, PhD, of the Alzheimer’s Association in Chicago, and co-authors in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
These advances create new possibilities to intervene before the onset of cognitive impairment, Weber and colleagues wrote. Targeting the earliest stages of Alzheimer’s, Weber said, “is similar to how doctors treat other diseases like heart disease and some cancers, where early detection and prevention are key parts of care.”
Read more HERE
People with Alzheimer’s disease often have other neurodegenerative conditions as well, including a less-understood disorder called frontotemporal lobar degeneration (FTLD). While a precise diagnosis of FTLD has only been possible during an autopsy, new research shows how clinicians may be able to diagnose people living with both Alzheimer’s and FTLD by evaluating neuropsychiatric symptoms.
In a study published in Neurology, researchers found that compared to patients who have either of the two types of dementia alone, having both Alzheimer’s disease and FTLD is associated with greater likelihood of having known neuropsychiatric symptoms of both diseases.
The findings could have important implications for patients and their caregivers, the researchers noted, because patients with both disorders may experience a more complex disease course, rapid decline or unique responses to disease-modifying treatments.
Read more HERE